CALGARY, ALBERTA--(MARKET WIRE)--Jul 20, 2007 -- Resverlogix Corp. (“Resverlogix”) (Toronto:RVX.TO - News) is pleased to announce today that the company has been notified that it’s abstract submission has been accepted. Resverlogix will make an oral presentation of key scientific data of its lead molecule RVX-208 at the 16th International Symposium for Drugs Affecting Lipid Metabolism (DALM). The presentation titled “A novel drug RVX-208 raises plasma apolipoprotein A-l and HDL cholesterol” will be presented by Dr. Norman Wong, Resverlogix co-founder and chairman of the scientific advisory board on the opening day of the conference October 4, 2007 in New York City.
